335 related articles for article (PubMed ID: 31805976)
1. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
2. Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS.
Wang R; Kang H; Zhang X; Nie Q; Wang H; Wang C; Zhou S
BMC Cancer; 2022 Feb; 22(1):214. PubMed ID: 35220945
[TBL] [Abstract][Full Text] [Related]
3. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
[TBL] [Abstract][Full Text] [Related]
4. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients.
Monteiro M; Moreira N; Pinto J; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Carvalho M; Guedes de Pinho P
J Cell Mol Med; 2017 Sep; 21(9):2092-2105. PubMed ID: 28378454
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
6. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
7. LC-MS-Based Plasma Metabolomics and Lipidomics Analyses for Differential Diagnosis of Bladder Cancer and Renal Cell Carcinoma.
Liu X; Zhang M; Cheng X; Liu X; Sun H; Guo Z; Li J; Tang X; Wang Z; Sun W; Zhang Y; Ji Z
Front Oncol; 2020; 10():717. PubMed ID: 32500026
[TBL] [Abstract][Full Text] [Related]
8. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
9. LC-MS based urine untargeted metabolomic analyses to identify and subdivide urothelial cancer.
Yang M; Liu X; Tang X; Sun W; Ji Z
Front Oncol; 2023; 13():1160965. PubMed ID: 37256175
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.
Cheng X; Liu X; Liu X; Guo Z; Sun H; Zhang M; Ji Z; Sun W
Front Oncol; 2018; 8():494. PubMed ID: 30450336
[No Abstract] [Full Text] [Related]
11. Urine metabolomic analysis in clear cell and papillary renal cell carcinoma: A pilot study.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Solmoirago MJ; Sánchez-González JV; Vera-Donoso CD; Martínez-Sarmiento M; España F; Navarro S; Medina P
J Proteomics; 2020 Apr; 218():103723. PubMed ID: 32126320
[TBL] [Abstract][Full Text] [Related]
12. Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC.
Liu X; Zhang M; Liu X; Sun H; Guo Z; Tang X; Wang Z; Li J; Li H; Sun W; Zhang Y
Front Oncol; 2019; 9():663. PubMed ID: 31380290
[TBL] [Abstract][Full Text] [Related]
13. Urine metabolomics analysis for kidney cancer detection and biomarker discovery.
Kim K; Aronov P; Zakharkin SO; Anderson D; Perroud B; Thompson IM; Weiss RH
Mol Cell Proteomics; 2009 Mar; 8(3):558-70. PubMed ID: 19008263
[TBL] [Abstract][Full Text] [Related]
14. Volatile metabolomic signature of bladder cancer cell lines based on gas chromatography-mass spectrometry.
Rodrigues D; Pinto J; Araújo AM; Monteiro-Reis S; Jerónimo C; Henrique R; de Lourdes Bastos M; de Pinho PG; Carvalho M
Metabolomics; 2018 Apr; 14(5):62. PubMed ID: 30830384
[TBL] [Abstract][Full Text] [Related]
15. Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Shimada S; Morozumi K; Sato M; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2020 Jul; 111(7):2570-2578. PubMed ID: 32350988
[TBL] [Abstract][Full Text] [Related]
16. Integrated transcriptomic and metabolomic analysis shows that disturbances in metabolism of tumor cells contribute to poor survival of RCC patients.
Popławski P; Tohge T; Bogusławska J; Rybicka B; Tański Z; Treviño V; Fernie AR; Piekiełko-Witkowska A
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):744-752. PubMed ID: 28012969
[TBL] [Abstract][Full Text] [Related]
17. Label-free screening of common urinary system tumors from blood plasma based on surface-enhanced Raman spectroscopy.
Xu Q; Li T; Lin J; Wu X
Photodiagnosis Photodyn Ther; 2024 Feb; 45():103900. PubMed ID: 38081568
[TBL] [Abstract][Full Text] [Related]
18. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA.
Nizioł J; Bonifay V; Ossoliński K; Ossoliński T; Ossolińska A; Sunner J; Beech I; Arendowski A; Ruman T
Anal Bioanal Chem; 2018 Jun; 410(16):3859-3869. PubMed ID: 29658093
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive urinary metabolomic approach for identifying kidney cancerr.
Kind T; Tolstikov V; Fiehn O; Weiss RH
Anal Biochem; 2007 Apr; 363(2):185-95. PubMed ID: 17316536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
